Burning Rock Biotech (BNR) Receivables (2019 - 2025)

Burning Rock Biotech's Receivables history runs 7 years deep, the most recent figure standing at $25.6 million for Q4 2025.

• In Q4 2025, Receivables rose 11.07% year-over-year to $25.6 million; the TTM figure through Dec 2025 stood at $25.6 million (up 11.07% YoY), while the FY2025 annual figure was $25.6 million, down 11.58% from the prior year.
• Receivables was $25.6 million for Q4 2025 at Burning Rock Biotech, down from $27.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $28.9 million in Q2 2023 to a low of -$2.2 million in Q2 2022.
• Historically, Receivables has averaged $21.3 million across 5 years, with a median of $23.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables tumbled 117.92% in 2022, then soared 1419.76% in 2023.
• A 5-year view of Receivables shows it stood at $21.1 million in 2021, then increased by 1.33% to $21.3 million in 2022, then slipped by 2.59% to $20.8 million in 2023, then grew by 11.13% to $23.1 million in 2024, then grew by 11.07% to $25.6 million in 2025.
• The last three Receivables figures came in at $25.6 million (Q4 2025), $27.5 million (Q3 2025), and $28.3 million (Q2 2025), per Business Quant data.